Filing Flows › Entrada Therapeutics (TRDA) › Next earnings date
Entrada Therapeutics (TRDA) earnings: beat the estimate
Entrada Therapeutics (TRDA) reported on Nov 5, 2026 and beat the EPS estimate: −$0.94 against −$0.99 (+4.9%). Revenue was $905K for Q3 2026, -44% year over year. It beat the EPS estimate in 80% of the quarters on record.
The last report
Entrada Therapeutics reported revenue of $905K for the third quarter 2026 (-44% Y/Y), net loss $39.7M. How it makes money → · Every quarter →
Entrada Therapeutics' latest quarter
Entrada Therapeutics, Q3 2026: revenue $905K (-44% year over year), net loss $39.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Entrada Therapeutics beat earnings?
Entrada Therapeutics (TRDA) reported on Nov 5, 2026 and beat the EPS estimate: −$0.94 against −$0.99 (+4.9%).
When does TRDA report earnings?
The next date is not set yet.
Does Entrada Therapeutics usually beat earnings?
It beat the consensus EPS estimate in 80% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.